News | December 05, 2021
Lupin and Biomm tie-up for pegfilgrastim in Brazil
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Nelarabine is in a class of medications called antimetabolites
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Biocon Biologics and Viatris co-developed the products
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Subscribe To Our Newsletter & Stay Updated
